<p>在全球贸易政策波动和通胀缓解的背景下，亚洲市场正在应对复杂的经济环境。对于关注小型或新兴公司的投资者来说，尽管 “便士股票” 这一术语已显过时，但仍然在可接受的价格点上蕴含增长潜力。这些股票在强劲的财务支持下可以提供显著的价值，成为那些寻求具有良好长期前景的隐藏宝石的投资者的有趣选择。</p>
<h3>亚洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Halcyon Technology (SET:HTECH)</td>
<td>THB2.64</td>
<td>THB792M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.445</td>
<td>SGD180.35M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Beng Kuang Marine (SGX:BEZ)</td>
<td>SGD0.176</td>
<td>SGD35.06M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.21</td>
<td>SGD8.7B</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.13</td>
<td>SGD858.72M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ever Sunshine Services Group (SEHK:1995)</td>
<td>HK$1.90</td>
<td>HK$3.28B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.39</td>
<td>HK$50.26B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.15</td>
<td>HK$725.59M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Goodbaby International Holdings (SEHK:1086)</td>
<td>HK$1.20</td>
<td>HK$2B</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.04</td>
<td>HK$1.7B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们亚洲便士股票筛选器中的 1,161 只股票的完整列表。</p>
<p>在这里，我们突出了一些我们筛选器中首选的股票。</p>
<h2>HighTide Therapeutics (SEHK:2511)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> HighTide Therapeutics, Inc.是一家生物制药公司，专注于在中国大陆发现、研究、开发和商业化代谢和消化疾病的疗法，市值为 14.2 亿港元。</p>
<p><strong>运营：</strong> HighTide Therapeutics, Inc.目前尚未报告任何具体的收入细分。</p>
<p><strong>市值：</strong> 14.2 亿港元</p>
<p>HighTide Therapeutics, Inc.是一家尚未产生收入的生物制药公司，最近宣布其主要化合物 HTD1801 在治疗 2 型糖尿病的第三阶段试验中取得了积极结果。尽管缺乏收入且当前处于亏损状态，但公司财务状况良好，短期资产超过负债，现金多于债务。管理团队经验丰富，尽管董事会相对较新。HighTide 的股票仍然高度波动，反映出典型的便士股票特征。即将提交的 HTD1801 新药申请如果获得中国监管机构的批准，可能会成为关键。</p>
<ul>
<li>在我们的财务健康报告中更深入地了解 HighTide Therapeutics 的潜力。</li>
<li>通过我们的公司历史业绩报告，获取 HighTide Therapeutics 过去趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6beb0d11-f4c0-43ce-b1c7-c5f6a6883836/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6beb0d11-f4c0-43ce-b1c7-c5f6a6883836/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 6 月 SEHK:2511 债务与股本历史及分析</p>
<h2>山东墨龙石油机械 (SEHK:568)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 山东墨龙石油机械有限公司及其子公司专注于能源设备产品和服务的设计、研发、生产和销售，业务覆盖中国及国际市场，市值为 30.6 亿港元。</p>
<p><strong>运营：</strong> 山东墨龙石油机械有限公司未报告具体的收入细分。</p>
<p><strong>市值：</strong> 30.6 亿港元</p>
<p>山东墨龙石油机械面临财务挑战与运营韧性的混合局面。尽管处于亏损状态，但公司保持了超过三年的正现金流，得益于 20 亿人民币的短期资产超过其负债。然而，其高达 201.3% 的净债务与股本比率和增加的债务水平突显了财务压力。最近的财报显示收入有所改善，但净收入较去年大幅下降，表明了便士股票的典型波动性。管理层缺乏经验可能会影响他们在应对这些复杂情况时的战略决策。</p>
<ul>
<li>在这份财务健康报告中解锁我们对山东墨龙石油机械股票的全面分析。</li>
<li>通过我们的详细历史业绩报告评估山东墨龙石油机械的过去业绩。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/20212d05-d35e-4ded-8efc-0c4129b90465/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/20212d05-d35e-4ded-8efc-0c4129b90465/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 6 月 SEHK:568 收入与支出细分</p>
<h2>重庆莱美药业 (SZSE:300006)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 重庆莱美药业有限公司专注于在中国进行药品的研发、生产和销售，市值为 39.2 亿人民币。</p>
<p><strong>运营：</strong> 公司的收入主要来自其在中国的业务，金额为 8.1287 亿人民币。</p>
<p><strong>市值：</strong> 39.2 亿人民币</p>
<p>重庆莱美药业面临典型便士股票的财务挑战，尽管收入增长至 1.984 亿人民币，但 2025 年第一季度报告的净亏损为 1378 万人民币。公司处于亏损状态，但改善了其债务状况，五年内将债务与股本比率从 74.9% 降低至 18.6%，并保持现金多于总债务，提供了超过三年的稳定现金流，即使自由现金流下降。15 亿人民币的短期资产足以覆盖负债，尽管持续的亏损需要其经验丰富的领导团队进行谨慎管理，平均任期超过八年。</p>
<ul>
<li>点击查看我们在重庆莱美药业财务健康报告中的详细发现。</li>
<li>查看我们的历史业绩报告，以获取关于重庆莱美药业的业绩记录的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fb40b6-ec17-4914-b36e-80810c43a600/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fb40b6-ec17-4914-b36e-80810c43a600/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300006 截至 2025 年 6 月的收入与支出明细</p>
<h2>接下来该怎么办？</h2>
<ul>
<li>点击此链接深入了解我们亚洲便士股票筛选器中的 1,161 家公司。</li>
<li>寻找替代机会？癌症的终结？这 23 只新兴的人工智能股票正在开发技术，以便早期识别改变生命的疾病，如癌症和阿尔茨海默病。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

山东墨龙

莱美药业

<p>HighTide Therapeutics 和另外两只亚洲便士股票在全球贸易政策波动和通胀缓解的背景下被认为是潜在的投资机会。HighTide 是一家生物制药公司，其糖尿病治疗的三期临床试验结果令人鼓舞，尽管尚未产生收入。山东墨龙面临财务挑战，但仍保持积极的现金流。重庆莱美药业改善了其债务状况，但报告了净亏损。这些股票反映了亚洲市场便士股票的波动性和潜力</p>

<p>Amidst a backdrop of fluctuating global trade policies and easing inflation, Asian markets have been navigating a complex economic landscape. For investors eyeing opportunities in smaller or newer companies, penny stocks—though an outdated term—still hold potential for growth at accessible price points. These stocks can offer notable value when backed by strong financials, making them intriguing options for those seeking hidden gems with promising long-term prospects.</p>
<div class="lb-trans"><p>在全球贸易政策波动和通胀缓解的背景下，亚洲市场正在应对复杂的经济环境。对于关注小型或新兴公司的投资者来说，尽管 “便士股票” 这一术语已显过时，但仍然在可接受的价格点上蕴含增长潜力。这些股票在强劲的财务支持下可以提供显著的价值，成为那些寻求具有良好长期前景的隐藏宝石的投资者的有趣选择。</p>
</div><h3>Top 10 Penny Stocks In Asia</h3>
<div class="lb-trans"><h3>亚洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Halcyon Technology (SET:HTECH)</td>
<td>THB2.64</td>
<td>THB792M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.445</td>
<td>SGD180.35M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Beng Kuang Marine (SGX:BEZ)</td>
<td>SGD0.176</td>
<td>SGD35.06M</td>
<td>✅ 4 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.21</td>
<td>SGD8.7B</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.13</td>
<td>SGD858.72M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Ever Sunshine Services Group (SEHK:1995)</td>
<td>HK$1.90</td>
<td>HK$3.28B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.39</td>
<td>HK$50.26B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.15</td>
<td>HK$725.59M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Goodbaby International Holdings (SEHK:1086)</td>
<td>HK$1.20</td>
<td>HK$2B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.04</td>
<td>HK$1.7B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Halcyon Technology (SET:HTECH)</td>
<td>THB2.64</td>
<td>THB792M</td>
<td>✅ 2 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.445</td>
<td>SGD180.35M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Beng Kuang Marine (SGX:BEZ)</td>
<td>SGD0.176</td>
<td>SGD35.06M</td>
<td>✅ 4 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD2.21</td>
<td>SGD8.7B</td>
<td>✅ 5 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>BRC Asia (SGX:BEC)</td>
<td>SGD3.13</td>
<td>SGD858.72M</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ever Sunshine Services Group (SEHK:1995)</td>
<td>HK$1.90</td>
<td>HK$3.28B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Bosideng International Holdings (SEHK:3998)</td>
<td>HK$4.39</td>
<td>HK$50.26B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.15</td>
<td>HK$725.59M</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Goodbaby International Holdings (SEHK:1086)</td>
<td>HK$1.20</td>
<td>HK$2B</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.04</td>
<td>HK$1.7B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 1,161 stocks from our Asian Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们亚洲便士股票筛选器中的 1,161 只股票的完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在这里，我们突出了一些我们筛选器中首选的股票。</p>
</div><h2>HighTide Therapeutics (SEHK:2511)</h2>
<div class="lb-trans"><h2>HighTide Therapeutics (SEHK:2511)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> HighTide Therapeutics, Inc. is a biopharmaceutical company focused on discovering, researching, developing, and commercializing therapies for metabolic and digestive diseases in Mainland China, with a market cap of HK$1.42 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> HighTide Therapeutics, Inc.是一家生物制药公司，专注于在中国大陆发现、研究、开发和商业化代谢和消化疾病的疗法，市值为 14.2 亿港元。</p>
</div><p><strong>Operations:</strong> HighTide Therapeutics, Inc. has not reported any specific revenue segments at this time.</p>
<div class="lb-trans"><p><strong>运营：</strong> HighTide Therapeutics, Inc.目前尚未报告任何具体的收入细分。</p>
</div><p><strong>Market Cap:</strong> HK$1.42B</p>
<div class="lb-trans"><p><strong>市值：</strong> 14.2 亿港元</p>
</div><p>HighTide Therapeutics, Inc., a pre-revenue biopharmaceutical company, recently announced positive Phase 3 trial results for its lead compound HTD1801 in treating type 2 diabetes mellitus. Despite its lack of revenue and current unprofitability, the company has a strong financial position with short-term assets exceeding liabilities and more cash than debt. The management team is experienced, although the board is relatively new. HighTide's stock remains highly volatile, reflecting typical penny stock characteristics. The upcoming NDA submission for HTD1801 could be pivotal if approved by China's regulatory authorities later this year.</p>
<div class="lb-trans"><p>HighTide Therapeutics, Inc.是一家尚未产生收入的生物制药公司，最近宣布其主要化合物 HTD1801 在治疗 2 型糖尿病的第三阶段试验中取得了积极结果。尽管缺乏收入且当前处于亏损状态，但公司财务状况良好，短期资产超过负债，现金多于债务。管理团队经验丰富，尽管董事会相对较新。HighTide 的股票仍然高度波动，反映出典型的便士股票特征。即将提交的 HTD1801 新药申请如果获得中国监管机构的批准，可能会成为关键。</p>
</div><ul>
<li>Take a closer look at HighTide Therapeutics' potential here in our financial health report.</li>
<li>Gain insights into HighTide Therapeutics' past trends and performance with our report on the company's historical track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的财务健康报告中更深入地了解 HighTide Therapeutics 的潜力。</li>
<li>通过我们的公司历史业绩报告，获取 HighTide Therapeutics 过去趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6beb0d11-f4c0-43ce-b1c7-c5f6a6883836/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/6beb0d11-f4c0-43ce-b1c7-c5f6a6883836/chart/debt-equity-history-analysis"/></p>
<p>SEHK:2511 Debt to Equity History and Analysis as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月 SEHK:2511 债务与股本历史及分析</p>
</div><h2>Shandong Molong Petroleum Machinery (SEHK:568)</h2>
<div class="lb-trans"><h2>山东墨龙石油机械 (SEHK:568)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Shandong Molong Petroleum Machinery Company Limited, along with its subsidiaries, focuses on the design, research and development, production, and sale of energy equipment products and services both in China and internationally, with a market cap of HK$3.06 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 山东墨龙石油机械有限公司及其子公司专注于能源设备产品和服务的设计、研发、生产和销售，业务覆盖中国及国际市场，市值为 30.6 亿港元。</p>
</div><p><strong>Operations:</strong> No specific revenue segments are reported for Shandong Molong Petroleum Machinery Company Limited.</p>
<div class="lb-trans"><p><strong>运营：</strong> 山东墨龙石油机械有限公司未报告具体的收入细分。</p>
</div><p><strong>Market Cap:</strong> HK$3.06B</p>
<div class="lb-trans"><p><strong>市值：</strong> 30.6 亿港元</p>
</div><p>Shandong Molong Petroleum Machinery has shown a mix of financial challenges and operational resilience. Despite being unprofitable, the company maintains a positive cash runway for over three years, supported by CN¥2 billion in short-term assets exceeding its liabilities. However, its high net debt to equity ratio of 201.3% and increased debt levels highlight financial strain. The recent earnings report shows improved revenue but a significant drop in net income compared to the previous year, indicating volatility typical of penny stocks. Management's lack of experience could impact strategic decisions as they navigate these complexities.</p>
<div class="lb-trans"><p>山东墨龙石油机械面临财务挑战与运营韧性的混合局面。尽管处于亏损状态，但公司保持了超过三年的正现金流，得益于 20 亿人民币的短期资产超过其负债。然而，其高达 201.3% 的净债务与股本比率和增加的债务水平突显了财务压力。最近的财报显示收入有所改善，但净收入较去年大幅下降，表明了便士股票的典型波动性。管理层缺乏经验可能会影响他们在应对这些复杂情况时的战略决策。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Shandong Molong Petroleum Machinery stock in this financial health report.</li>
<li>Assess Shandong Molong Petroleum Machinery's previous results with our detailed historical performance reports.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这份财务健康报告中解锁我们对山东墨龙石油机械股票的全面分析。</li>
<li>通过我们的详细历史业绩报告评估山东墨龙石油机械的过去业绩。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/20212d05-d35e-4ded-8efc-0c4129b90465/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/20212d05-d35e-4ded-8efc-0c4129b90465/chart/revenue-and-expenses-breakdown"/></p>
<p>SEHK:568 Revenue &amp; Expenses Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月 SEHK:568 收入与支出细分</p>
</div><h2>Chongqing Lummy Pharmaceutical (SZSE:300006)</h2>
<div class="lb-trans"><h2>重庆莱美药业 (SZSE:300006)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Chongqing Lummy Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and sale of pharmaceutical products in China with a market cap of CN¥3.92 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 重庆莱美药业有限公司专注于在中国进行药品的研发、生产和销售，市值为 39.2 亿人民币。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily generated from its operations in China, amounting to CN¥812.87 million.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其在中国的业务，金额为 8.1287 亿人民币。</p>
</div><p><strong>Market Cap:</strong> CN¥3.92B</p>
<div class="lb-trans"><p><strong>市值：</strong> 39.2 亿人民币</p>
</div><p>Chongqing Lummy Pharmaceutical faces financial challenges typical of penny stocks, with a net loss of CN¥13.78 million reported for Q1 2025 despite revenue growth to CN¥198.4 million. The company is unprofitable but has improved its debt profile, reducing the debt-to-equity ratio from 74.9% to 18.6% over five years and maintaining more cash than total debt, providing a stable cash runway exceeding three years even if free cash flow declines. Short-term assets of CN¥1.5 billion comfortably cover liabilities, though ongoing losses necessitate careful management by its experienced leadership team averaging over eight years in tenure.</p>
<div class="lb-trans"><p>重庆莱美药业面临典型便士股票的财务挑战，尽管收入增长至 1.984 亿人民币，但 2025 年第一季度报告的净亏损为 1378 万人民币。公司处于亏损状态，但改善了其债务状况，五年内将债务与股本比率从 74.9% 降低至 18.6%，并保持现金多于总债务，提供了超过三年的稳定现金流，即使自由现金流下降。15 亿人民币的短期资产足以覆盖负债，尽管持续的亏损需要其经验丰富的领导团队进行谨慎管理，平均任期超过八年。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Chongqing Lummy Pharmaceutical's financial health report.</li>
<li>Review our historical performance report to gain insights into Chongqing Lummy Pharmaceutical's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击查看我们在重庆莱美药业财务健康报告中的详细发现。</li>
<li>查看我们的历史业绩报告，以获取关于重庆莱美药业的业绩记录的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a3fb40b6-ec17-4914-b36e-80810c43a600/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/a3fb40b6-ec17-4914-b36e-80810c43a600/chart/revenue-and-expenses-breakdown"/></p>
<p>SZSE:300006 Revenue &amp; Expenses Breakdown as at Jun 2025</p>
<div class="lb-trans"><p>SZSE:300006 截至 2025 年 6 月的收入与支出明细</p>
</div><h2>Where To Now?</h2>
<div class="lb-trans"><h2>接下来该怎么办？</h2>
</div><ul>
<li>Click this link to deep-dive into the 1,161 companies within our Asian Penny Stocks screener.</li>
<li>Looking For Alternative Opportunities? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击此链接深入了解我们亚洲便士股票筛选器中的 1,161 家公司。</li>
<li>寻找替代机会？癌症的终结？这 23 只新兴的人工智能股票正在开发技术，以便早期识别改变生命的疾病，如癌症和阿尔茨海默病。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

HighTide Therapeutics 及其他两只亚洲低价股值得密切关注